These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 29547128)

  • 1. Is gliclazide a new antidiabetic drug implicated in the pathogenesis of ocular mucous membrane pemphigoid?
    Cozzani E; Di Zenzo G; Cioni M; Javor S; Altieri M; Anselmi L; Parodi A
    Eur J Dermatol; 2018 Jun; 28(3):396-397. PubMed ID: 29547128
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute generalized exanthematous pustulosis induced by gliclazide: a case report.
    Contreras-Steyls M; Vílchez-Márquez F; Mota A; Moyano B; Herrera-Ceballos E
    Int J Dermatol; 2013 Dec; 52(12):1591-3. PubMed ID: 24261739
    [No Abstract]   [Full Text] [Related]  

  • 3. Eosinophilic pleural effusion due to gliclazide.
    Tzanakis N; Bouros D; Siafakas N
    Respir Med; 2000 Jan; 94(1):94. PubMed ID: 10714487
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug-induced ocular cicatricial pemphigoid: a series of clinico-pathological reports.
    Butt Z; Kaufman D; McNab A; McKelvie P
    Eye (Lond); 1998; 12 ( Pt 2)():285-90. PubMed ID: 9683956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gliclazide-induced acute hepatitis.
    Dourakis SP; Tzemanakis E; Sinani C; Kafiri G; Hadziyannis SJ
    Eur J Gastroenterol Hepatol; 2000 Jan; 12(1):119-21. PubMed ID: 10656221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
    Mbanya JC; Al-Sifri S; Abdel-Rahim A; Satman I
    Diabetes Res Clin Pract; 2015 Aug; 109(2):226-32. PubMed ID: 26003888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Viardot A
    Ther Umsch; 2017; 74(8):423-431. PubMed ID: 29461148
    [No Abstract]   [Full Text] [Related]  

  • 9. The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
    Clemens KK; McArthur E; Dixon SN; Fleet JL; Hramiak I; Garg AX
    Can J Diabetes; 2015 Aug; 39(4):308-16. PubMed ID: 25840942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab-related mucous membrane pemphigoid.
    Sibaud V; Vigarios E; Siegfried A; Bost C; Meyer N; Pages-Laurent C
    Eur J Cancer; 2019 Nov; 121():172-176. PubMed ID: 31586756
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hypoglycemia].
    Gupta PS; Green AN; Chowdhury TA
    Praxis (Bern 1994); 2011 Oct; 100(21):1303-5. PubMed ID: 22012756
    [No Abstract]   [Full Text] [Related]  

  • 12. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
    Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes.
    Braatvedt GD
    N Z Med J; 1997 May; 110(1044):189-90. PubMed ID: 9201206
    [No Abstract]   [Full Text] [Related]  

  • 16. [The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus].
    Li GW; Pan CY; Gao Y; Yuan SY; Yang WY; Xing XY; Tian H; Guo XH; Li HB
    Zhonghua Nei Ke Za Zhi; 2004 Jul; 43(7):510-4. PubMed ID: 15312405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic progressive ocular cicatrization.
    Plotkin A; Alagheband M; Trevino J
    Arch Dermatol; 2000 Jan; 136(1):114-5, 117-8. PubMed ID: 10632215
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythroderma secondary to gliclazide: a case report.
    Ozuguz P; Kacar SD; Ozuguz U; Karaca S; Tokyol C
    Cutan Ocul Toxicol; 2014 Dec; 33(4):342-4. PubMed ID: 24641117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progression of a case of ocular pemphigoid over five years].
    Kameche I; Karaouat F; Garout R; Hamchi T
    J Fr Ophtalmol; 2013 Jan; 36(1):90-1. PubMed ID: 23201344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.